The recommendation for Enflonsia is indicated for respiratory syncytial virus prevention in infants under eight months of age, expanding protection options ahead of the 2025–2026 season.

A comprehensive meta-analysis by the University of Melbourne links common respiratory viruses like COVID-19, RSV, and ...

A new study by the University of Oxford, published in the journal npj Vaccines, shows that a vaccine against respiratory ...

The CDC's vaccine advisory committee voted on Thursday to recommend infants receive a newer monoclonal antibody shot for ...

An outside group of experts agreed that the CDC should recommend a new antibody drug that offers protection against RSV for ...

A newly configured federal vaccine panel's June 25 action is expected to improve options to protect infants from potentially ...

Robert F. Kennedy Jr. had fired all 17 members of a key vaccine panel. Now his new panel recommended a new infant RSV vaccine ...

Respiratory syncytial virus (RSV) is a leading cause of acute lower respiratory infections (ALRTIs) in children under five and poses a persistent threat to child health worldwide.

A group of outside advisers to the US Centers for Disease Control and Prevention voted 5-2 to recommend use of a new shot ...

The CDC's Advisory Committee on Immunization Practices (ACIP) has issued new vaccine recommendations affecting RSV and flu ...

Mortality was higher in the RSV cohort, with a 10.1% death rate, compared to 5.5% for flu. RSV infection showed a 52% higher ...

Protection against RSV derived from preF IgG antibodies waned 6 months after infection in an analysis of patients with confirmed disease and household contacts.